Recent

% | $
Quotes you view appear here for quick access.

Genomic Health Inc. Message Board

  • terry_amln terry_amln Jan 31, 2014 2:19 AM Flag

    GHDX announces more data on Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Can

    Genomic Health Announces Results of Oncotype DX(R) Colon Cancer Studies Presented at 2014 American Society of Clinical Oncology Gastrointestinal Cancer (ASCO GI) Symposium

    New data show real-life impact of Oncotype DX on treatment decisions, underscore clinical validity and utility of the test GHDX) today announced results from the Oncotype DX® colon cancer test studies that were recently presented at the 2014 American Society of Clinical Oncology Gastrointestinal Cancer Symposium (ASCO GI). Presentations highlighted the robust body of clinical evidence for the Oncotype DX colon cancer test and its real-life impact on patient and physician treatment decisions, underscoring the practice-changing value of this test.
    Prospective study demonstrated real-life impact on physician and patient treatment decisions
    Through an analysis of physician recommendations and patient treatment preferences before and after receiving the Oncotype DX colon cancer test results, this study demonstrated that the test greatly increased concordance between physician and patient treatment choice (from 66 percent to 96 percent). Furthermore, the evaluation showed that the quantitative information provided by the Recurrence Score® result influenced a majority of patients' treatment decisions (85 percent) and physicians' treatment recommendations (69 percent), and it increased physicians' confidence in their own recommendations (84 percent). Patients' anxiety was also significantly reduced, which may improve adherence to their treatment plan and ultimately lead to better health outcomes.

    "The additional information provided by the Oncotype DX test enables me and my patients to make better informed decisions about their individual treatment," said Steven Alberts, M.D., chair of the Division of Medical Oncology at Mayo Clinic Cancer Center, Roche

 
GHDX
27.03-0.05(-0.18%)Aug 3 4:00 PMEDT